Veterinary Drugs Company Seeking Loan in Hyderabad, India
Well established animal vaccine manufacturer offering high-capacity production for national livestock health under government contracts.
| Established | 10-20 year(s) |
| Employees | 100 - 500 |
| Legal Entity | Private Limited Company |
| Reported Sales | Nil |
| Run Rate Sales | Nil |
| EBITDA Margin | Nil |
| Industries | Veterinary Drugs |
| Locations | Hyderabad |
| Local Time | 3:53 PM Asia / Kolkata |
| Listed By | Business Owner / Director |
| Status | Active |
Seeking Loan
USD
4.1 million
for
20.0%
annual interest,
3
years
(Native Currency: INR 350,000,000)
Reason: Seeking an immediate loan to bridge short-term working capital needs and kickstart production of its...
View More
Collateral Available: USD 8.2 million
Includes physical assets worth
USD
53 million
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Documents
GST Certificate
(170.3 KB)
Business Overview
- Hyderabad-based specialty pharmaceutical company specializing in manufacturing animal vaccines, with a focus on FMD and Brucella vaccines.
- A state-of-the-art facility designed to produce up to 200 million vaccine doses annually.
- Currently in the initial stage of production, with a capacity utilization of 150 million doses per year, scalable up to 200 million doses based on demand.
- The flagship product, the FMD vaccine, plays a crucial role in supporting India’s livestock health mission and meeting urgent national requirements.
- Previously supplied Brucella vaccines worth INR 50 crore to the Government of India, demonstrating strong strategic partnerships in the public sector.
- Operates on a secure government procurement-based revenue model, ensuring bulk demand and predictable cash flow.
- Recognized for its high-quality products and reliable execution, fostering strong relationships with central and state veterinary departments.
- The business holds a valid GST certificate, Drug License, and USFDA approval.
- Currently non-operational, with production in its early phase.
- A state-of-the-art facility designed to produce up to 200 million vaccine doses annually.
- Currently in the initial stage of production, with a capacity utilization of 150 million doses per year, scalable up to 200 million doses based on demand.
- The flagship product, the FMD vaccine, plays a crucial role in supporting India’s livestock health mission and meeting urgent national requirements.
- Previously supplied Brucella vaccines worth INR 50 crore to the Government of India, demonstrating strong strategic partnerships in the public sector.
- Operates on a secure government procurement-based revenue model, ensuring bulk demand and predictable cash flow.
- Recognized for its high-quality products and reliable execution, fostering strong relationships with central and state veterinary departments.
- The business holds a valid GST certificate, Drug License, and USFDA approval.
- Currently non-operational, with production in its early phase.
Products & Services Overview
Top product is the FMD vaccine, produced at a high-capacity, licensed facility to meet urgent national demand under India's livestock health mission.Brucella vaccines are also manufactured, previously supplied to the Government of India. These vaccines are used by government veterinary departments for mass immunization of cattle and buffaloes.
Assets Overview
Tangible assets include a fully-owned INR 450 crore vaccine manufacturing facility, advanced production equipment, quality control labs, cold storage units, office infrastructure, and utility systems.Intangible assets include government drug licenses, proprietary production know-how, supplier and government relationships, experienced technical teams, and a proven execution track record with national vaccine programs.
Facilities Overview
Vaccine manufacturing facility spans over 1,00,000 sq. ft. of built-up area across multiple floors, designed to meet WHO-GMP and national regulatory standards. The facility is located in Hyderabad, and is company-owned (not leased) and houses dedicated zones for antigen production, formulation, filling, cold storage, and quality control, ensuring end-to-end vaccine manufacturing under one roof.
Capitalization Overview
Currently funded through a combination of promoter equity and institutional debt. The business has INR 80 crore in unsecured loans, INR 60 crore in bank loans, and INR 20 crore in vendor dues, totaling INR 160 crore in liabilities.The company is owned by four shareholders with the following equity distribution: 55%, 17%, 15%, and 13%, respectively.
Recent Activity
-
1 week, 6 days agoDirector, Hyderabad, Financial Consultant connected with the Business
-
Earlier than 15 daysFounder, Bengaluru, Investment Bank connected with the Business
-
Earlier than 15 daysManaging Partner And Head M&A, Hyderabad, Financial Consultant connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
2 Investors contacted this Business this month.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 124,000+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses